Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1431-1434

  Benton, Christopher B ^a   Ravandi, Farhad ^b   Andreeff, Michael ^b   Kadia, Tapan ^b   Ruvolo, Vivian ^b   Qiu, Peng ^a   Wheeler, David A ^c   Garcia Manero, Guillermo ^b   Cortes, Jorge ^b   Kantarjian, Hagop M ^b   Konopleva, Marina ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; FLUDARABINE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; RETINOIC ACID; VALPROIC ACID; ANTINEOPLASTIC AGENT; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 7; CYTOGENETICS; DIPLOIDY; DISEASE COURSE; DNA METHYLATION; FOLLOW UP; GENE MUTATION; HUMAN; LETTER; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; CASE REPORT; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MUTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA METHYLATION; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MUTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84901329040     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.840777     Document Type: Letter

References (16)

1. Valk P JM, Verhaak R GW, Beijen M A, et al. Prognostically useful gene-expression profi les in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-1628. (Pubitemid 38528701
2. Yen K E, Bittinger M A, Su S M, et al. Cancer-Associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 2010; 29: 6409-6417
3. Dang L, White D W, Gross S, et al. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744
4. Ward PS, Patel J, Wise DR, et al. The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234
5. Figueroa M E, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic diff erentiation. Cancer Cell 2010; 18: 553-567
6. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell diff erentiation. Nature 2012; 483: 474-478
7. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia wiThNPM1 mutation without FLT3 internal tandem duplication. JClin Oncol 2010; 28: 3636-3643
8. Marcucci G, Maharry K, Wu Y-Z, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. JClin Oncol 2010; 28: 2348-2355
9. Ravandi F, Patel K, Luthra R, et al. Prognostic signifi cance of alterations in IDH enzyme isoforms in patients wiThAML treated wiThhigh-Dose cytarabine and idarubicin. Cancer 2012; 118: 2665-2673
10. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039
11. Garcia-Manero G, Kantarjian H M, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-Aza-2'-Deoxycytidine wiThvalproic acid in patients wiThleukemia. Blood 2006; 108 : 3271-3279
12. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-Azacytidine, valproic acid, and all-Trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302-2308. (Pubitemid 47523148
13. Borthakur G, Huang X, Kantarjian H, et al. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 2010; 51: 73-78
14. Colombo T, Rossi C, D'Incalci M. Antagonism of 5-Aza-2'-Deoxycytidine antileukemic activity by concomitant treatment wiThcytarabine. Cancer Treat Rep 1986; 70: 1451-1453. (Pubitemid 17005131
15. Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase II trial. Blood 2011; 118: 3824-3831
16. Wang F, Travins J, Delabarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular diff erentiation. Science 2013; 340: 622-626